[Corticosteroidogenesis inhibitors. II. A new cortico-adrenal inhibitor: amino-glutethimide (16,038Ba)].
D015068:17-Ketosteroids / Q000652:urine; D000305:Adrenal Cortex Hormones / Q000096:biosynthesis*; D000307:Adrenal Gland Diseases / Q000139:chemically induced; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000311:Adrenal Glands / Q000187:drug effects*; D000309:Adrenal Insufficiency / Q000139:chemically induced; D000616:Aminoglutethimide / Q000009:adverse effects / Q000494:pharmacology; D000814:Aniline Compounds / Q000494:pharmacology*; D000927:Anticonvulsants / Q000494:pharmacology*; D003480:Cushing Syndrome / Q000188:drug therapy; D005260:Female; D006406:Hematoma / Q000139:chemically induced; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy; D007037:Hypothyroidism / Q000139:chemically induced; D008297:Male; D009336:Necrosis / Q000139:chemically induced; D011728:Pyridones / Q000494:pharmacology*
D015068:17-Ketosteroids; D000305:Adrenal Cortex Hormones; D000814:Aniline Compounds; D000927:Anticonvulsants; D011728:Pyridones; D000616:Aminoglutethimide
Les inhibiteurs de la cortico-stéröidogenèse. II. Un nouvel inhibiteur de la cortico-surrénale: l'aminoglutéthimide (16'038 Ba)